[go: up one dir, main page]

MX2012014521A - Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion. - Google Patents

Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.

Info

Publication number
MX2012014521A
MX2012014521A MX2012014521A MX2012014521A MX2012014521A MX 2012014521 A MX2012014521 A MX 2012014521A MX 2012014521 A MX2012014521 A MX 2012014521A MX 2012014521 A MX2012014521 A MX 2012014521A MX 2012014521 A MX2012014521 A MX 2012014521A
Authority
MX
Mexico
Prior art keywords
levocetirizine
montelukast
formulations
methods
common cold
Prior art date
Application number
MX2012014521A
Other languages
English (en)
Inventor
Bruce Chandler May
Original Assignee
Bruce Chandler May
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bruce Chandler May filed Critical Bruce Chandler May
Publication of MX2012014521A publication Critical patent/MX2012014521A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Las modalidades descritas en la presente incluyen métodos y formulaciones para el tratamiento de influenza, resfriado común, e inflamación aguda asociada. Los métodos y formulaciones incluyen pero no están limitados a métodos y formulaciones para administrar concentraciones efectivas de levocetirizina y montelukast a un paciente en necesidad del mismo. Los métodos y formulaciones pueden comprender elementos de liberación convencional y/o elementos de liberación modificada, proporcionando la administración del fármaco al paciente.
MX2012014521A 2010-06-16 2011-06-15 Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion. MX2012014521A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35552010P 2010-06-16 2010-06-16
PCT/US2011/040562 WO2011159821A1 (en) 2010-06-16 2011-06-15 Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation

Publications (1)

Publication Number Publication Date
MX2012014521A true MX2012014521A (es) 2013-05-20

Family

ID=45348536

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012014521A MX2012014521A (es) 2010-06-16 2011-06-15 Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
MX2015009169A MX352824B (es) 2010-06-16 2011-06-15 Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015009169A MX352824B (es) 2010-06-16 2011-06-15 Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.

Country Status (10)

Country Link
US (5) US9044479B2 (es)
EP (2) EP2799071B1 (es)
JP (2) JP5781606B2 (es)
KR (2) KR101801864B1 (es)
CN (2) CN103002896A (es)
AU (1) AU2011268342B2 (es)
CA (1) CA2802853C (es)
ES (1) ES2705244T3 (es)
MX (2) MX2012014521A (es)
WO (1) WO2011159821A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012014521A (es) 2010-06-16 2013-05-20 Bruce Chandler May Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
KR20150138849A (ko) 2013-03-13 2015-12-10 인플래머토리 리스폰스 리서치, 아이엔씨. 레보세티리진 및 몬테루카스트의 자가면역질환의 치료 용도
AU2014249534B2 (en) * 2013-03-13 2018-08-30 IRR, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
KR20150138848A (ko) * 2013-03-13 2015-12-10 인플래머토리 리스폰스 리서치, 아이엔씨. 레보세티리진 및 몬테루카스트의 과민증 치료 용도
ES2770760T3 (es) * 2013-03-13 2020-07-03 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de lesiones traumáticas
EP3193875B1 (en) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
WO2017210417A1 (en) * 2016-06-03 2017-12-07 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of radiation-mediated conditions
WO2019004776A2 (en) * 2017-06-30 2019-01-03 Hanmi Pharm. Co., Ltd. COMPRESSED COMPOSITE CHEMICAL COMPRISING LEOVETITIZINE AND MONTELUKAST WITH IMPROVED STABILITY AND MEDICATION OBSERVANCE, AND PROCESS FOR PREPARING THE SAME
MA52924A (fr) * 2017-07-05 2021-04-28 Jiangyin Mucocare Pharmaceutical Co Ltd Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule
US20230142221A1 (en) * 2020-04-10 2023-05-11 Kamal Khan Mubarak Compositions and methods for modulating ace2 receptor
EP4153178A4 (en) 2020-05-19 2024-06-05 Irr, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
WO2022011210A1 (en) * 2020-07-10 2022-01-13 Sean Downing Treatment for severe acute respiratory illness associated with coronavirus
KR102481517B1 (ko) * 2021-08-30 2022-12-27 주식회사 클라시아 약제학적 제제
TR2021018192A1 (tr) * 2021-11-22 2023-06-21 İstanbul Medi̇pol Üni̇versi̇tesi̇ Anti̇-vi̇ral etki̇ gösterebi̇lecek yeni̇ i̇laç formülasyonlarinin hazirlanmasi ve covi̇d-19?a karşi etki̇si̇ni̇n araştirilmasi
US20230190734A1 (en) * 2021-12-16 2023-06-22 IRR, Inc. Levocetirizine and montelukast in the treatment of coronavirus disease and symptoms thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
US5211958A (en) 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
US5147637A (en) 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
DE69226372T2 (de) 1991-11-14 1999-04-01 Alliance Pharmaceutical Corp., San Diego, Calif. Vorrichtung zur teilweisen flüssigen beatmung mit fluorkohlenwasserstoffen
JPH09510952A (ja) 1993-10-06 1997-11-04 ザ ケネディー インスティチュート オブ リューマトロジー 自己免疫疾患および炎症性疾患の治療
JP2001511134A (ja) 1997-01-24 2001-08-07 オートイミューン インク メトトレキサートと組合せる耐性化を用いる自己免疫疾患の治療
WO1999032125A1 (en) * 1997-12-23 1999-07-01 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
AU2470299A (en) 1998-01-27 1999-08-09 Nutramax Laboratories, Inc. Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
PL203216B1 (pl) * 2000-07-28 2009-09-30 Immupharm Aps Zastosowanie lecznicze hydroksyetylorutozydów, kompozycja farmaceutyczna zawierająca hydroksyetylorutozydy oraz sól Zn²⁺ i/lub kompleks Zn²⁺, zestaw zawierający hydroksyetylorutozydy oraz sól Zn²⁺ i/lub kompleks Zn²⁺, oraz zastosowanie lecznicze kompozycji farmaceutycznej lub zestawu zawierającego hydroksyetylorutozydy oraz sól Zn²⁺ i/lub kompleks Zn²⁺
US7718198B2 (en) 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
RU2286784C2 (ru) 2001-06-28 2006-11-10 ЮСиБи ФАРШИМ С.А. Таблетка, содержащая цетиризин и псевдоэфедрин
WO2003002109A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
AU2003232805A1 (en) 2002-05-24 2003-12-12 Carl-Fr. Coester Pharmaceutical active substance combination and the use thereof
US7291331B1 (en) * 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
WO2004080414A2 (en) 2003-03-12 2004-09-23 Mullally John P Composition and method for treating inflammations by reducing c-reactive protein
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
RU2411956C2 (ru) 2004-10-05 2011-02-20 Дженентек, Инк. Способ лечения васкулита
FR2881823B1 (fr) 2005-02-08 2007-03-16 Siemens Vdo Automotive Sas Utilisation de la magneto-impedance sur un capteur de position sans contact et capteur correspondant
US20070244128A1 (en) * 2005-11-04 2007-10-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
JP5107933B2 (ja) 2005-12-21 2012-12-26 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 炎症性疾患の治療に使用する、抗コリン作用薬類、β２−アドレナリン受容体のアゴニスト類、抗ロイコトリエン（ロイコトリエン受容体のアンタゴニスト）類、グルココルチコイド類および／またはＰＤＥ４阻害剤類の新規配合薬
US7589076B2 (en) 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
WO2008100539A1 (en) 2007-02-12 2008-08-21 Michalis Nicolaou Treatment of copd, gastro-esophageal reflux disease (gerd), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, lra drugs, anti-h1 and/or anti-h2 drugs
WO2008106429A2 (en) 2007-02-26 2008-09-04 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
EP2175856A4 (en) 2007-08-15 2011-08-24 Chemagis Ltd NOVEL PROCESS FOR THE PREPARATION OF HIGH-PURITY LEVOCETRIXIN AND ITS SALTS
WO2009052625A1 (en) 2007-10-25 2009-04-30 Merck Frosst Canada Ltd. Novel crystalline salts of montelukast
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
CA2703672A1 (en) 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US8946265B2 (en) 2009-03-02 2015-02-03 Generics [Uk] Limited Process for the preparation of lenalidomide
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
AU2011209754A1 (en) 2010-01-28 2012-07-26 Merck Sharp & Dohme Corp. Pharmaceutical compositions for the treatment of pain and other indicatons
MX2012014521A (es) * 2010-06-16 2013-05-20 Bruce Chandler May Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
WO2012013566A1 (en) 2010-07-28 2012-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and inflammatory diseases
TR201009398A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Fiziksel özellikleri geliştirilmiş tablet formülasyonları
JP5996553B2 (ja) 2010-12-30 2016-09-21 ジブ エム．ディー． ハリシュ， 果実および／または野菜との口腔接触に起因する口腔アレルギー症状の表面適用による予防および／または処置のための調製物
BR112013026064A2 (pt) 2011-04-13 2019-09-24 Revalesio Corp composições e métodos para inibir e/ou modular células t efetoras envolvidas em doença inflamatória neurodegenerativa
EP2520292A1 (en) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
KR20130009553A (ko) 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
JP5860960B2 (ja) 2011-07-26 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キノリン類及び医薬としてのそれらの使用
CN102895661A (zh) 2011-07-28 2013-01-30 中国科学院上海药物研究所 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
CN103505731A (zh) 2012-06-15 2014-01-15 中国药科大学 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
US20150322049A1 (en) 2012-12-13 2015-11-12 Ludwig Aigner Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
KR20150138849A (ko) 2013-03-13 2015-12-10 인플래머토리 리스폰스 리서치, 아이엔씨. 레보세티리진 및 몬테루카스트의 자가면역질환의 치료 용도
AU2014249534B2 (en) 2013-03-13 2018-08-30 IRR, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
ES2770760T3 (es) 2013-03-13 2020-07-03 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de lesiones traumáticas
KR20150138848A (ko) 2013-03-13 2015-12-10 인플래머토리 리스폰스 리서치, 아이엔씨. 레보세티리진 및 몬테루카스트의 과민증 치료 용도
EP3193875B1 (en) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
WO2017210417A1 (en) 2016-06-03 2017-12-07 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of radiation-mediated conditions

Also Published As

Publication number Publication date
CA2802853A1 (en) 2011-12-22
US20160175301A1 (en) 2016-06-23
MX352824B (es) 2017-12-11
CA2802853C (en) 2016-07-26
JP2015180701A (ja) 2015-10-15
EP2799071A1 (en) 2014-11-05
EP2799071B1 (en) 2018-10-17
EP2582373A4 (en) 2013-10-30
WO2011159821A1 (en) 2011-12-22
US20150231133A1 (en) 2015-08-20
EP2582373A1 (en) 2013-04-24
JP5781606B2 (ja) 2015-09-24
KR20130050952A (ko) 2013-05-16
ES2705244T3 (es) 2019-03-22
AU2011268342A1 (en) 2013-01-31
KR20150038736A (ko) 2015-04-08
US20190298714A1 (en) 2019-10-03
US9044479B2 (en) 2015-06-02
CN103002896A (zh) 2013-03-27
AU2011268342B2 (en) 2014-12-04
US10537568B2 (en) 2020-01-21
US20130085124A1 (en) 2013-04-04
US20200323843A1 (en) 2020-10-15
CN107308161A (zh) 2017-11-03
KR101801864B1 (ko) 2017-11-27
HK1199815A1 (en) 2015-07-24
JP2013528654A (ja) 2013-07-11

Similar Documents

Publication Publication Date Title
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
MX360045B (es) Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX369385B (es) Productos para cicatrizar heridas tisulares.
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
WO2015066647A3 (en) Ionic liquids for transdermal drug delivery
MX2019002669A (es) Composicion farmaceutica para usarse en el tratamiento de la malnutricion en un sujeto que exhibe un trastorno de espectro de autismo (asd).
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2015005798A (es) Terapia de combinacion.
EP3818991A3 (en) Compositions and methods for treating diseases
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
WO2014153385A3 (en) Methods of treating metabolic disorders
MX377510B (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
HK1219896A1 (zh) 使用4-氨基-2-(2，6-二氧代-呱啶-3-基)-异吲哚啉-1，3-二酮治疗和控制中枢神经系统癌症的方法和组合物
MX2015005993A (es) Composiciones y metodos para el tratamiento de displasia ectodermica.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2014006662A (es) Direccionamiento de en2, pax2, y/o defb1 para tratamiento de afecciones de la próstata.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: INFLAMMATORY RESPONSE RESEARCH, INC.

FG Grant or registration